ATE540107T1 - Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate - Google Patents

Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate

Info

Publication number
ATE540107T1
ATE540107T1 AT10002316T AT10002316T ATE540107T1 AT E540107 T1 ATE540107 T1 AT E540107T1 AT 10002316 T AT10002316 T AT 10002316T AT 10002316 T AT10002316 T AT 10002316T AT E540107 T1 ATE540107 T1 AT E540107T1
Authority
AT
Austria
Prior art keywords
vkorc1
vitamin
coumarin
derivatives
therapeutic target
Prior art date
Application number
AT10002316T
Other languages
English (en)
Inventor
Johannes Oldenburg
Clemens R Mueller-Reible
Andreas Fregin
Tim-Matthias Strom
Simone Rost
Original Assignee
Baxter Int
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34520024&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE540107(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Int, Baxter Healthcare Sa filed Critical Baxter Int
Application granted granted Critical
Publication of ATE540107T1 publication Critical patent/ATE540107T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/027—New breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0276—Knockout animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/26—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving oxidoreductase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y101/00—Oxidoreductases acting on the CH-OH group of donors (1.1)
    • C12Y101/04—Oxidoreductases acting on the CH-OH group of donors (1.1) with a disulfide as acceptor (1.1.4)
    • C12Y101/04001—Vitamin-K-epoxide reductase (warfarin-sensitive) (1.1.4.1)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
AT10002316T 2003-10-14 2004-10-12 Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate ATE540107T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51104103P 2003-10-14 2003-10-14

Publications (1)

Publication Number Publication Date
ATE540107T1 true ATE540107T1 (de) 2012-01-15

Family

ID=34520024

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04790318T ATE466074T1 (de) 2003-10-14 2004-10-12 Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
AT10002316T ATE540107T1 (de) 2003-10-14 2004-10-12 Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT04790318T ATE466074T1 (de) 2003-10-14 2004-10-12 Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate

Country Status (13)

Country Link
US (5) US7939250B2 (de)
EP (3) EP1673450B1 (de)
JP (2) JP4777251B2 (de)
AT (2) ATE466074T1 (de)
AU (2) AU2004283246B2 (de)
CA (1) CA2542017A1 (de)
DE (1) DE602004026897D1 (de)
DK (3) DK2272951T3 (de)
ES (3) ES2515216T3 (de)
HK (1) HK1141834A1 (de)
PL (2) PL2189523T3 (de)
PT (2) PT1673450E (de)
WO (1) WO2005040367A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1842920B2 (de) 2003-09-23 2017-06-21 University Of North Carolina At Chapel Hill Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
GB0324044D0 (en) 2003-10-14 2003-11-19 Astrazeneca Ab Protein
JP4777251B2 (ja) * 2003-10-14 2011-09-21 バクスター・インターナショナル・インコーポレイテッド ビタミンｋエポキシド還元酵素複合体サブユニット１ｖｋｏｒｃ１、クマリンおよびその誘導体の治療標的
EP1781779A2 (de) * 2004-08-02 2007-05-09 Novozymes A/S Erzeugung von diversität in polypeptiden
CA2583904C (en) * 2004-10-18 2018-01-09 University Of Washington Methods and compositions for predicting drug responses
US7445896B2 (en) 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
DK1853700T3 (da) * 2005-02-28 2013-01-07 Baxter Int Rekombinant co-ekspression af vitamin-k-epoxid-reduktase-underenhed 1 til forbedring af vitamin-k-afhængig proteinekspression
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
CN101198696B (zh) 2005-04-13 2014-02-26 阿斯利康(瑞典)有限公司 包含产生需要γ-羧化的蛋白质用的载体的宿主细胞
WO2007110869A2 (en) * 2006-03-28 2007-10-04 Tel Hashomer Medical Research Infrastructure And Services Ltd. Methods and kits for determining predisposition to warfarin resistance
US8206967B2 (en) 2007-07-06 2012-06-26 Medimmune Limited Method for production of recombinant human thrombin
US20110183906A1 (en) 2008-04-24 2011-07-28 Celtic Pharma Peg Ltd. Factor ix conjugates with extended half-lives
US20110243958A1 (en) * 2008-10-15 2011-10-06 President And Fellows Of Harvard College Antimicrobial agents that target bacterial vkor
WO2011003153A1 (en) 2009-07-10 2011-01-13 Csl Limited Method of increasing the expression yield of vitamin k-dependent proteins
US9631002B2 (en) 2010-12-21 2017-04-25 The University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin K-dependent proteins
TWI600766B (zh) 2012-08-09 2017-10-01 財團法人工業技術研究院 用於偵測一目標核苷酸序列中之一特定區域的一突變及／或多形性的套組
WO2015044292A1 (en) * 2013-09-26 2015-04-02 Universitat Autonoma De Barcelona Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN105177153B (zh) * 2015-09-30 2018-04-24 南通市疾病预防控制中心 一种黄胸鼠pcr鉴定引物及鉴定方法
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
CN109880889B (zh) * 2019-04-08 2022-12-06 厦门市妇幼保健院(厦门市优生优育服务中心、厦门大学附属妇女儿童医院、厦门市林巧稚妇女儿童医院) 华法林药物靶点基因特定位点甲基化水平定量检测的引物及其方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2189523A (en) * 1938-11-05 1940-02-06 Alexander A Poch Sprinkler head shut-off device
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0127839B1 (de) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Verfahren zur Herstellung eines rekombinanten Baculovirus-Expressionsvektors
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
ATE87659T1 (de) 1986-09-02 1993-04-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB8822584D0 (en) 1988-09-27 1988-11-02 Abco Technology Ltd Steam boiler system
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
WO1991001372A1 (en) 1989-07-17 1991-02-07 New England Medical Center Hospitals, Inc. VITAMIN K-DEPENDENT η-CARBOXYLASE
WO1992001795A1 (en) 1990-07-23 1992-02-06 Zymogenetics, Inc. Gamma-carboxylase and methods of use
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5169784A (en) 1990-09-17 1992-12-08 The Texas A & M University System Baculovirus dual promoter expression vector
US5268275A (en) 1991-05-08 1993-12-07 The University Of North Carolina At Chapel Hill Vitamin K-dependent carboxylase
WO1993006213A1 (en) 1991-09-23 1993-04-01 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5698765A (en) 1991-12-02 1997-12-16 The Ontario Cancer Institute Mouse having a disrupted CD4 gene
WO1993018144A1 (en) 1992-03-05 1993-09-16 The Trustees Of Columbia University Of The City Of New York Recombination activating gene deficient animal
US5625122A (en) 1992-04-24 1997-04-29 The Ontario Cancer Institute Mouse having a disrupted lck gene
JP3741447B2 (ja) 1992-10-23 2006-02-01 中外製薬株式会社 エンドセリン−１遺伝子の機能が欠損したマウス
DE19625049A1 (de) 1996-06-22 1998-01-02 Inst Pflanzengenetik & Kultur Transgenes, nicht-menschliches Säugetier, das ein zusätzliches DNA-Reparaturgen enthält
AUPO864097A0 (en) 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
US5896337A (en) 1998-02-23 1999-04-20 Micron Technology, Inc. Circuits and methods for multi-level data through a single input/ouput pin
JP2002532056A (ja) * 1998-07-10 2002-10-02 インサイト・ファーマスーティカルズ・インコーポレイテッド ヒト輸送タンパク質相同体
WO2000043003A1 (en) 1999-01-21 2000-07-27 Darwin Discovery Limited The therapeutic use of r-warfarin as anticoagulant
BR0114374A (pt) 2000-10-02 2003-12-30 Novo Nordisk As Preparação compreendendo uma pluralidade de polipeptìdeos de fator vii, métodos para a determinação do padrão de glicoforma de fator vii e de polipeptìdeos relacionados com fator vii, e para a produção da dita preparação, formulação farmacêutica, métodos para o tratamento de uma sìndrome responsiva a fator vii, para a prevenção de sangramento indesejado, para a prevenção de coagulação sanguìnea indesejada, e para prevenção de reações mediadas por fator de tecido, e, uso da preparação
CA2441755A1 (en) * 2001-03-21 2003-05-08 Human Genome Sciences, Inc. Human secreted proteins
CA2453183C (en) 2001-07-12 2016-05-10 University Of Massachusetts In vivo production of small interfering rnas that mediate gene silencing
JP4549027B2 (ja) * 2002-02-04 2010-09-22 アース製薬株式会社 ネズミ用毒餌剤及びその安定化方法
EP1842920B2 (de) * 2003-09-23 2017-06-21 University Of North Carolina At Chapel Hill Zellen, die Vitamin-K-Reduktase und Vitamin-K-abhängiges Protein coexprimieren und deren Anwendung zur Verbesserung der Produktivität von diesem Vitamin-K-abhängigen Protein
JP4777251B2 (ja) * 2003-10-14 2011-09-21 バクスター・インターナショナル・インコーポレイテッド ビタミンｋエポキシド還元酵素複合体サブユニット１ｖｋｏｒｃ１、クマリンおよびその誘導体の治療標的
DK1853700T3 (da) 2005-02-28 2013-01-07 Baxter Int Rekombinant co-ekspression af vitamin-k-epoxid-reduktase-underenhed 1 til forbedring af vitamin-k-afhængig proteinekspression
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
US8647868B2 (en) 2005-12-02 2014-02-11 Wake Forest University Health Sciences Compositions and methods for increasing production of recombinant gamma-carboxylated proteins
WO2007075976A2 (en) 2005-12-21 2007-07-05 Inspiration Biopharmaceuticals, Inc. Method of producing biologically active vitamin k dependent proteins by recombinant methods
JP5829793B2 (ja) 2007-03-14 2015-12-09 エンドサイト・インコーポレイテッドＥｎｄｏｃｙｔｅ， Ｉｎｃ． 結合性リガンドが結合したツブリシンの薬剤送達結合体

Also Published As

Publication number Publication date
EP2272951B1 (de) 2014-07-23
ATE466074T1 (de) 2010-05-15
US7939250B2 (en) 2011-05-10
JP2007512002A (ja) 2007-05-17
US20050271644A1 (en) 2005-12-08
HK1141834A1 (en) 2010-11-19
ES2515216T3 (es) 2014-10-29
US20110154520A1 (en) 2011-06-23
ES2344413T3 (es) 2010-08-26
EP1673450B1 (de) 2010-04-28
DK1673450T3 (da) 2010-08-23
PL2189523T3 (pl) 2012-05-31
AU2009212805A1 (en) 2009-09-17
US20170240867A1 (en) 2017-08-24
AU2004283246A1 (en) 2005-05-06
EP2189523B1 (de) 2012-01-04
DK2272951T3 (da) 2014-10-13
DE602004026897D1 (de) 2010-06-10
EP2272951A1 (de) 2011-01-12
EP2189523A1 (de) 2010-05-26
EP1673450A1 (de) 2006-06-28
PT2189523E (pt) 2012-01-24
PL1673450T3 (pl) 2010-10-29
AU2004283246B2 (en) 2009-07-23
US20090094708A1 (en) 2009-04-09
PT1673450E (pt) 2010-05-11
JP4777251B2 (ja) 2011-09-21
CA2542017A1 (en) 2005-05-06
DK2189523T3 (da) 2012-03-12
US20130318640A1 (en) 2013-11-28
WO2005040367A1 (en) 2005-05-06
JP2011013231A (ja) 2011-01-20
ES2379764T3 (es) 2012-05-03

Similar Documents

Publication Publication Date Title
ATE466074T1 (de) Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate
DK1831362T3 (da) Syreaktive svampeproteaser
ES2353814T3 (es) Proteinas n-glicosiladas recombinantes de celulas procariotas.
DK1673457T3 (da) Nye svampeproteiner og nukleinsyrer, der koder for disse
SG162834A1 (en) Refolding of recombinant proteins
CO5721011A2 (es) Elementos de respuesta al estrogeno de bmp-2 y metodos de uso de los mismos
MX2008001865A (es) Proteinas de fusion de albumina.
BRPI0519930A2 (pt) composição oral, e, método para inibir e/ou tratar uma condição inflamatória oral em um indivìduo mamìfero
DK1648931T3 (da) Multifunktionelle cytokiner
SG149000A1 (en) Gag binding proteins
DE60206885D1 (de) Agarase und gen dafür
ATE378353T1 (de) Neurotrophe faktoren
WO2007060213A3 (en) Erythropoietin polypeptides and uses thereof
DE60313866D1 (de) Polypeptide mit alpha-h alpha amino acid amide racemase aktivitität und nukleinsäuren kodierend dafür
ATE315638T1 (de) Oxalacetat-hydrolase defiziente fungale wirtszellen
ATE547519T1 (de) Gerinnungsfaktor-vii-polypeptide
ATE513043T1 (de) Gegen denaturierungsmittel stabile und/oder proteaseresistente, chaperonähnliche oligomere proteine, diese kodierende polynukleotide sowie ihre verwendungen
ATE557092T1 (de) Bv8-nukleinsäuren und polypeptide mit mitogener aktivität
ATE464320T1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
DK1594526T3 (da) Anvendelse af HSP20 til fremmelse af sårheling og/eller reduktion af ardannelse
AR015756A1 (es) Fragmento aislado de acidos nucleicos que codifica toda o una porcion sustancial de una proteina reguladora del ciclo celular en plantas y semillas, genquimerico, celula huesped transformada, polipeptido, metodo para alterar el nivel de expresion de dichas proteinas en una celula huesped, metodos pa
DK0422217T3 (da) Human, rekombinant, placental ribonucleaseinhibitor og fremgangsmåde til produktion
DK2186898T3 (da) Blomstrings-induktion
WO2003104449A3 (en) IMPROVEMENTS IN PROTEIN PRODUCTION